Table 1.
Summary of study characteristics
| Study (year), Ref. [Publication dates] | Type of study | Total numberof subjects randomized/vaccinated(N) |
Vaccine strains in QIV | Vaccine strains in TIV | Country | Vaccine manufacturer |
Ethnicity(%) |
|---|---|---|---|---|---|---|---|
| Greenberg10 [2013] | open-label phase II |
590 | A/Brisbane/59/2007[H1N1] | TIV-Vic: A/Brisbane/59/2007[H1N1] | United States | Sanofi Pasteur Swiftwater, PA, USA |
White (88.8) Asian (0.35) others (10.85) |
| A/Uruguay/716/2007 [H3N2] | A/Uruguay/716/2007 [H3N2] | ||||||
| B/Brisbane/60/2008[B/Vic] | B/Brisbane/60/2008[B/Vic] | ||||||
| B/Florida/04/2006[B/Yam] | TIV-Yam: A/Brisbane/59/2007[H1N1] |
||||||
| A/Uruguay/716/2007 [H3N2] | |||||||
| B/Florida/04/2006[B/Yam] | |||||||
| Pépin12 [2013] | double-blind for QIV group open-label for TIV/Yam group phase III |
1,565 | A/California/07/2009[H1N1] | TIV-Vic: A/California/07/2009[H1N1] |
France Germany |
Sanofi Pasteur | White (98.7) Asian (0.5) others (0.8) |
| A/Victoria/210/2009 [H3N2] | A/Victoria/210/2009 [H3N2] | ||||||
| B/Brisbane/60/2008[B/Vic] | B/Brisbane/60/2008[B/Vic] | ||||||
| B/Florida/04/2006[B/Yam] | TIV-Yam: A/California/07/2009[H1N1] |
||||||
| A/Victoria/210/2009 [H3N2] | |||||||
| B/Florida/04/2006[B/Yam] | |||||||
| Wang15 [2017] | double-blind Phase III |
1,832 | A/California/7/2009[H1N1] | TIV-Vic: A/California/7/2009[H1N1] | Lianyungang City from China | QIV: Jiangsu GDK Biotechnology Co., Ltd, China TIV:Changsheng Biology Science & Technology Co. Ltd, China |
White (0) Asian (100) others (0) |
| A/Switzerland/9715293/2013[H3N2] | A/Switzerland/9715293/2013[H3N2] | ||||||
| B/Brisbane/60/2008[B/Vic] | B/Brisbane/60/2008[B/Vic] | ||||||
| B/Phuket/3073/2013[B/Yam] | TIV-Yam: A/California/7/2009[H1N1] |
||||||
| A/Switzerland/9715293/2013[H3N2] | |||||||
| B/Phuket/3073/2013[B/Yam] | |||||||
| Sesay13 [2018] | double-blinded for QIV group and TIV/Yam single-blinded for TIV/Vic phase III |
2,225 | A/California/7/2009[H1N1] | TIV-Vic: A/California/7/2009[H1N1] | France, Germany Poland |
Sanofi Pasteur, Lyon, France |
White (99.14) Asian (NA) others (0.86) |
| A/Texas/50/2012 [H3N2] | A/Texas/50/2012 [H3N2] | ||||||
| B/Brisbane/60/2008[B/Vic] | B/Brisbane/60/2008[B/Vic] | ||||||
| B/Massachusetts/2/2012[B/Yam] | TIVYam: A/California/7/2009[H1N1] |
||||||
| A/Texas/50/2012 [H3N2] | |||||||
| B/Massachusetts/2/2012[B/Yam] | |||||||
| Witte13 [2018] | double-blind Phase III |
1,980 | A/California/7/2009[H1N1] | TIV/Vic: A/California/7/2009[H1N1] | Belgium Germany Hungary Latvia Lithuania |
Abbott Biologicals B.V | White(99.5) Asian(0.2) Others(0.3) |
| A/Texas/50/2012[H3N2] | A/Texas/50/2012[H3N2] | ||||||
| B/Brisbane/60/2008[B/Vic] | B/Brisbane/60/2008[B/Vic] | ||||||
| B/Massachusetts/2/2012[B/Yam] | TIV/Yam: A/California/7/2009[H1N1] |
||||||
| A/Texas/50/2012[H3N2] | |||||||
| B/Massachusetts/2/2012[B/Yam] | |||||||
| Sharma [2018] | single blind phase II/III |
350 | A/California/7/2009/[H1N1] | TIV-Yam: | Indian | QIV: M/s Cadila Healthcare Limited, India TIV: Sanofi Pasteur India Private Limited |
White(0) Asian(100) Others(0) |
| A/Switzerland/9715293/2013[H3N2] | A/California/7/2009/[H1N1] | ||||||
| B/Brisbane/60/2008[B/Vic] | A/Switzerland/9715293/2013[H3N2] | ||||||
| B/Phuket/3073/2013[B/Yam] | B/Phuket/3073/2013[B/Yam] |
QIV: quadrivalent influenza vaccine; TIV: trivalent influenza vaccine; All the QIV and TIV were standard-dose
NA: Not available
White: Caucasian and Hispanic were included.